Veru Inc VERU Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$2.12 up $0.06, 2.91% at close Nov 6
Last close · Previous close $2.06
- Market cap
- $34.03MAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$2.12down $0.35, 14.17%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.06Nov 5
- Volume137.15KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume157.43KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.04 to $7.33; now $2.12
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
VERU trailed the S&P 500 in all 7 periods.
| Period | VERU and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VERU: down 14.2% S&P 500: down 5.6% | VERU trailed the S&P 500 by 8.6 percentage points Trailed |
| 3M | VERU: down 8.2% S&P 500: down 4.1% | VERU trailed the S&P 500 by 4.1 percentage points Trailed |
| YTD | VERU: down 0.9% S&P 500: up 8.7% | VERU trailed the S&P 500 by 9.6 percentage points Trailed |
| 1Y | VERU: down 15.9% S&P 500: up 10.9% | VERU trailed the S&P 500 by 26.8 percentage points Trailed |
| Long term | ||
| 3Y | VERU: down 78.4% S&P 500: up 75.0% −40.0% vs +20.5% a year | VERU trailed the S&P 500 by 153.4 percentage points Trailed |
| 5Y | VERU: down 97.5% S&P 500: up 67.8% −52.2% vs +10.9% a year | VERU trailed the S&P 500 by 165.3 percentage points Trailed |
| 10Y | VERU: down 77.0% S&P 500: up 313.1% −13.7% vs +15.2% a year | VERU trailed the S&P 500 by 390.1 percentage points Trailed |
$10,000 invested in VERU 10 years ago (Nov 4, 2016) would be worth about $2,304 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
VERU trailed the S&P 500 in all 7 periods.
| Period | VERU and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VERU: down 14.2% S&P 500: down 5.6% | VERU trailed the S&P 500 by 8.6 percentage points Trailed |
| 3M | VERU: down 8.2% S&P 500: down 4.3% | VERU trailed the S&P 500 by 3.9 percentage points Trailed |
| YTD | VERU: down 0.9% S&P 500: up 7.8% | VERU trailed the S&P 500 by 8.7 percentage points Trailed |
| 1Y | VERU: down 15.9% S&P 500: up 9.7% | VERU trailed the S&P 500 by 25.6 percentage points Trailed |
| Long term | ||
| 3Y | VERU: down 78.4% S&P 500: up 68.8% −40.0% vs +19.1% a year | VERU trailed the S&P 500 by 147.2 percentage points Trailed |
| 5Y | VERU: down 97.5% S&P 500: up 56.9% −52.2% vs +9.4% a year | VERU trailed the S&P 500 by 154.4 percentage points Trailed |
| 10Y | VERU: down 77.0% S&P 500: up 252.6% −13.7% vs +13.4% a year | VERU trailed the S&P 500 by 329.6 percentage points Trailed |
$10,000 invested in VERU 10 years ago (Nov 4, 2016) would be worth about $2,304 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$237.80
Closing high on . Now 99.1% below that record.
Split-adjusted daily closes since Feb 11, 1999.
Stock splits
1
1-for-10 on . Share counts adjust after each split.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −76.54%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $10.92MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own VERU DCF in Excel. Value Veru with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$13.61M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Sep 30, 2024) | $0.00 | −$8.53M | Paused See the note under the price. |
| Q1 FY25 (Dec 31, 2024) | $0.00 | −$8.95M | Paused See the note under the price. |
| Q2 FY25 (Mar 31, 2025) | $0.00 | −$7.90M | Paused See the note under the price. |
| Q3 FY25 (Jun 30, 2025) | $0.00 | −$7.33M | Paused See the note under the price. |
| Q4 FY25 (Sep 30, 2025) | $0.00 | $1.45M | Paused See the note under the price. |
| Q1 FY26 (Dec 31, 2025) | $0.00 | −$5.33M | Paused See the note under the price. |
| Q2 FY26 (Mar 31, 2026) | $0.00 | −$2.74M | Paused See the note under the price. |
| Q3 FY26 (Jun 30, 2026) | $0.00 | −$6.99M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Sep 30, 2021) | $61.26M | $7.39M | Paused See the note under the price. |
| FY22 (Sep 30, 2022) | $39.35M | −$84.04M | Paused See the note under the price. |
| FY23 (Sep 30, 2023) | $16.30M | −$93.15M | Paused See the note under the price. |
| FY24 (Sep 30, 2024) | $0.00 | −$37.80M | Paused See the note under the price. |
| FY25 (Sep 30, 2025) | $0.00 | −$22.73M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$26.04MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$26.04MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $23.37MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $25.79MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$2.68MAs of Jun 30, 2026
- Net cash$23.11MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 4.42As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.09As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −45.9%Last 12 months
Over the last 12 months, Veru lost money: its net loss was 45.9% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −34.6%Last 12 months
Over the last 12 months, Veru’s net loss was 34.6% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $0.000 |
| 2017 | $0.000 |
| 2018 | $0.000 |
| 2019 | $0.000 |
| 2020 | $0.000 |
| 2021 | $0.000 |
| 2022 | $0.000 |
| 2023 | $0.000 |
| 2024 | $0.000 |
| 2025 | $0.000 |
| 2026 (to date) | $0.000 |
Dividend details
- $0.00Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- 0.00%; 5-yr low 0.29%, 5-yr high 7.17%Last 12 months
Dividends paid over the last 12 months as a share of the Nov 6 close. The bar shows where that yield sits in its range over the past five years; the median was 1.19%.
- $0.70Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
- Payout ratioPausedLast 12 months
See the note under the price.
About Veru Inc
Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic diseases, oncology, and ARDS. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The Company does not intend to undertake further development of sabizabulin for the treatment of viral-induced ARDS until we obtain funding from government grants, pharmaceutical company partnerships, or other similar third-party external sources.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Florida, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
VERU news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
VERU stock FAQ
What is VERU stock’s price today?
Veru (VERU) traded at $2.12 at the close on , up $0.06 (2.91%) from the previous close of $2.06. Over the past 52 weeks it has traded between $2.04 and $7.33.
If you invested $1,000 in VERU 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in VERU on would be worth about $230 at the close on , a total return of −77.0%. The same $1,000 would be worth $25 if invested five years ago, $841 if invested one year ago, and $207 if invested 20 years ago. Past performance doesn’t predict future returns.
What is Veru’s market cap?
Veru’s market capitalization is about $34.0 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $2.12 (how market cap works).
Does VERU pay a dividend?
Veru hasn’t paid a dividend in the last twelve months.
What is VERU’s 52-week high and low?
Over the past 52 weeks VERU has traded as low as $2.04 and as high as $7.33. At $2.12 at the close on , it is 71.1% below that high and 3.9% above the low.
What is VERU’s all-time high?
VERU’s highest closing price was $237.80 on , adjusted for stock splits. At $2.12 at the close on , it is 99.1% below that record.
Has VERU stock ever split?
Yes, once: 1-for-10 on .
How has VERU stock performed?
Including dividends and measured to the close on , VERU has returned −0.9% so far this year and −15.9% over the past year, and −97.5% over five years (−52.2% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Veru in?
Veru is in the Healthcare sector and the Biotechnology industry, and is headquartered in Florida, USA.
What exchange does VERU trade on?
Veru trades on the Nasdaq under the ticker symbol VERU. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.